Literature DB >> 9916917

Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions.

P Van Der Voorn1, J Tekstra, R H Beelen, C P Tensen, P Van Der Valk, C J De Groot.   

Abstract

The pathology of multiple sclerosis (MS) is characterized by breakdown of the blood-brain barrier (BBB), accompanied by infiltration of macrophages and T lymphocytes into the central nervous system (CNS). The migration of these cells into the CNS parenchyma may be partly regulated by chemokines. The aim of this study was therefore to investigate the cellular localization of the potent monocyte- and T-cell-attracting chemokine monocyte chemoattractant protein (MCP)-1 by immunohistochemistry on postmortem brain tissue from MS and normal control cases. Brain tissue samples of six MS patients and four patients without a history of brain disease were neuropathologically classified according to characteristic (immuno)histochemical staining patterns. Frozen tissue sections of active demyelinating MS lesions, chronic active demyelinating MS lesions, and normal control brain were immunohistochemically stained with a monoclonal antibody directed against MCP-1. In active demyelinating MS lesions as well as in chronic active MS lesions, reactive hypertrophic astrocytes were strongly immunoreactive for MCP-1, whereas perivascular and parenchymal foamy macrophages did not express MCP-1 protein. These results suggest a significant role for the beta-chemokine MCP-1, synthesized in vivo by reactive hypertrophic astrocytes, in the recruitment and activation of myelin-degrading macrophages and thereby contributing to the evolution of MS lesions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9916917      PMCID: PMC1853444          DOI: 10.1016/S0002-9440(10)65249-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  25 in total

Review 1.  The pathological evolution of multiple sclerosis.

Authors:  W I McDonald; D H Miller; D Barnes
Journal:  Neuropathol Appl Neurobiol       Date:  1992-08       Impact factor: 8.090

Review 2.  Chemokines and tissue injury.

Authors:  M B Furie; G J Randolph
Journal:  Am J Pathol       Date:  1995-06       Impact factor: 4.307

Review 3.  Pathogenesis of multiple sclerosis.

Authors:  C Ffrench-Constant
Journal:  Lancet       Date:  1994-01-29       Impact factor: 79.321

4.  Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody.

Authors:  M Takeya; T Yoshimura; E J Leonard; K Takahashi
Journal:  Hum Pathol       Date:  1993-05       Impact factor: 3.466

5.  Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases.

Authors:  R Miyagishi; S Kikuchi; T Fukazawa; K Tashiro
Journal:  J Neurol Sci       Date:  1995-04       Impact factor: 3.181

6.  Chemokine expression in murine experimental allergic encephalomyelitis.

Authors:  R Godiska; D Chantry; G N Dietsch; P W Gray
Journal:  J Neuroimmunol       Date:  1995-05       Impact factor: 3.478

7.  Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats.

Authors:  S R Ruuls; J Bauer; K Sontrop; I Huitinga; B A 't Hart; C D Dijkstra
Journal:  J Neuroimmunol       Date:  1995-02       Impact factor: 3.478

8.  Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats.

Authors:  I Huitinga; S R Ruuls; S Jung; N Van Rooijen; H P Hartung; C D Dijkstra
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

9.  Monocyte/macrophage differentiation in early multiple sclerosis lesions.

Authors:  W Brück; P Porada; S Poser; P Rieckmann; F Hanefeld; H A Kretzschmar; H Lassmann
Journal:  Ann Neurol       Date:  1995-11       Impact factor: 10.422

10.  Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages.

Authors:  I Huitinga; N van Rooijen; C J de Groot; B M Uitdehaag; C D Dijkstra
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

View more
  82 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

2.  Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions.

Authors:  L A Boven; L Montagne; H S Nottet; C J De Groot
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 4.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

Review 5.  Innate immunity in the central nervous system.

Authors:  Richard M Ransohoff; Melissa A Brown
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 6.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

7.  N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Naoki Tokuhara; Kana Namiki; Mai Uesugi; Chihiro Miyamoto; Makoto Ohgoh; Katsutoshi Ido; Takashi Yoshinaga; Toshihiko Yamauchi; Junro Kuromitsu; Sadao Kimura; Norimasa Miyamoto; Yoshitoshi Kasuya
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

8.  Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons.

Authors:  Rory D Spence; Amy J Wisdom; Yuan Cao; Haley M Hill; Chandler R L Mongerson; Briana Stapornkul; Noriko Itoh; Michael V Sofroniew; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

9.  Lipocalin-2 protein deficiency ameliorates experimental autoimmune encephalomyelitis: the pathogenic role of lipocalin-2 in the central nervous system and peripheral lymphoid tissues.

Authors:  Youngpyo Nam; Jong-Heon Kim; Minchul Seo; Jae-Hong Kim; Myungwon Jin; Sangmin Jeon; Jung-wan Seo; Won-Ha Lee; So Jin Bing; Youngheun Jee; Won Kee Lee; Dong Ho Park; Hyun Kook; Kyoungho Suk
Journal:  J Biol Chem       Date:  2014-05-07       Impact factor: 5.157

10.  Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls.

Authors:  Delgertsetseg Chuluundorj; Scott A Harding; David Abernethy; Anne Camille La Flamme
Journal:  Immunol Cell Biol       Date:  2016-10-03       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.